Edwards Lifesciences (EW) announced the appointment of Theodora Mistras as the company’s corporate vice president and CFO, effective at the end of May. Mistras will succeed Scott Ullem, who announced in October his planned transition from the CFO role. Mistras joins Edwards from Viatris, where she has served as CFO since March 2024, leading the company’s global finance organization and overseeing financial planning, reporting and operational finance across a complex, global business. Prior to Viatris, she was a managing director in healthcare investment banking at Citigroup Global Markets, and earlier in her career held senior leadership roles in healthcare investment banking at Goldman Sachs. Mistras brings decades of healthcare leadership experience helping guide corporate boards and executive teams on corporate finance, strategy and investor relations. She holds a bachelor’s degree in international studies from the University of Pennsylvania and a bachelor’s degree in economics from the Wharton School.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- Edwards Lifesciences Maintained at Buy as Strong Q1 Results and RESILIA Durability Data Support Elevated 2026 Outlook and Unchanged $97 Price Target
- Edwards Lifesciences announces 10-year results from Commence aortic trial
- Edwards Lifesciences price target raised to $110 from $104 at Barclays
- Edwards Lifesciences price target raised to $90 from $89 at Truist
- Edwards Lifesciences price target raised to $93 from $92 at Evercore ISI
